CXCR4 and cancer: In contrast, EPI-X4 as endogenous antagonist, being not useful as tumor-homing peptide, is highly efficient in suppressing signaling from CXCR4 and in inhibiting CXCL12-induced cancer cell migration in vitro and inflammatory cell infiltration in vivo [25].